• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Targeting Secondary and Tertiary Resistance to BRAF Inhibition in BRAF V600E-Mutated Metastatic Colorectal Cancer.

作者信息

Akhoundova Dilara, Pietge Heike, Hussung Saskia, Kiessling Michael, Britschgi Christian, Zoche Martin, Rechsteiner Markus, Weber Achim, Fritsch Ralph M

机构信息

Department of Medical Oncology and Hematology, University Hospital of Zurich, Zurich, Switzerland.

Department of Pathology and Molecular Pathology, University Hospital of Zurich, Zurich, Switzerland.

出版信息

JCO Precis Oncol. 2021 Nov;5:1082-1087. doi: 10.1200/PO.21.00107.

DOI:10.1200/PO.21.00107
PMID:34994629
Abstract
摘要

相似文献

1
Targeting Secondary and Tertiary Resistance to BRAF Inhibition in BRAF V600E-Mutated Metastatic Colorectal Cancer.针对BRAF V600E突变型转移性结直肠癌对BRAF抑制的继发性和三发性耐药
JCO Precis Oncol. 2021 Nov;5:1082-1087. doi: 10.1200/PO.21.00107.
2
BRAF-Directed Therapy in Metastatic Colorectal Cancer.BRAF靶向治疗在转移性结直肠癌中的应用
Cancer J. 2016 May-Jun;22(3):175-8. doi: 10.1097/PPO.0000000000000189.
3
BRAF mutation in metastatic colorectal cancer.转移性结直肠癌中的BRAF突变
N Engl J Med. 2009 Jul 2;361(1):98-9. doi: 10.1056/NEJMc0904160.
4
Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study.BRAF 突变型转移性结直肠癌中国患者的临床病理特征及治疗疗效：一项回顾性观察研究
Chin J Cancer. 2017 Oct 16;36(1):81. doi: 10.1186/s40880-017-0247-y.
5
Improvements in Clinical Outcomes for -Mutant Metastatic Colorectal Cancer.KRAS 突变型转移性结直肠癌临床结局的改善
Clin Cancer Res. 2020 Sep 1;26(17):4435-4441. doi: 10.1158/1078-0432.CCR-19-3809. Epub 2020 Apr 6.
6
How should BRAF V600E-mutated colorectal cancer be treated?BRAF V600E突变型结直肠癌应如何治疗？
Clin Adv Hematol Oncol. 2018 May;16(5):333-335.
7
Encorafenib: A Review in Metastatic Colorectal Cancer with a BRAF V600E Mutation.恩考芬尼：治疗伴有 BRAF V600E 突变的转移性结直肠癌的研究进展。
Drugs. 2021 May;81(7):849-856. doi: 10.1007/s40265-021-01501-5. Epub 2021 Apr 29.
8
[New drug approval: Encorafenib-metastatic colorectal cancers with BRAF V600E mutation after systemic chemotherapy].[新药获批：恩考芬尼用于全身化疗后BRAF V600E突变的转移性结直肠癌]
Bull Cancer. 2020 Nov;107(11):1086-1088. doi: 10.1016/j.bulcan.2020.08.012. Epub 2020 Oct 9.
9
Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer.西妥昔单抗联合索拉非尼、帕尼单抗联合瑞戈非尼超适应证用药，为 V600E BRAF 突变转移性结直肠癌患者实施个体化治疗。
Cancer Biol Ther. 2013 Aug;14(8):703-10. doi: 10.4161/cbt.25191. Epub 2013 Jun 13.
10
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.野生型BRAF是转移性结直肠癌对帕尼单抗或西妥昔单抗产生反应所必需的。
J Clin Oncol. 2008 Dec 10;26(35):5705-12. doi: 10.1200/JCO.2008.18.0786. Epub 2008 Nov 10.

引用本文的文献

1
Targeting the MAP kinase pathway in colorectal cancer: A journey in personalized medicine.靶向结直肠癌中的丝裂原活化蛋白激酶通路：个性化医疗之旅。
Clin Cancer Res. 2025 May 1. doi: 10.1158/1078-0432.CCR-25-0107.
2
Real-World Data of Patients with V600E-Mutated Metastatic Colorectal Cancer Treated with Trifluridine/Tipiracil.三氟尿苷/替匹嘧啶治疗V600E突变转移性结直肠癌患者的真实世界数据
Cancers (Basel). 2024 Dec 12;16(24):4140. doi: 10.3390/cancers16244140.
3
CDK4/6 inhibition to resensitize BRAF/EGFR inhibitor in patient-derived BRAF/PTEN-mutant colon cancer cells.
在患者来源的BRAF/PTEN突变结肠癌细胞中，抑制CDK4/6可使BRAF/EGFR抑制剂重新敏感。
Transl Cancer Res. 2024 Jul 31;13(7):3695-3703. doi: 10.21037/tcr-24-20. Epub 2024 Jul 12.
4
Targeting G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver.针对结直肠癌中的 G12C 突变：综述：箭袋中的新箭。
Int J Mol Sci. 2024 Mar 14;25(6):3304. doi: 10.3390/ijms25063304.
5
Ezrin Inhibition Overcomes Acquired Resistance to Vemurafenib in BRAFV600E-Mutated Colon Cancer and Melanoma Cells In Vitro.Ezrin 抑制克服 BRAFV600E 突变的结肠癌细胞和黑色素瘤细胞对威罗非尼的获得性耐药。
Int J Mol Sci. 2023 Aug 17;24(16):12906. doi: 10.3390/ijms241612906.
6
Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications.解析结直肠癌的复杂性：异质性、克隆进化及临床意义
Cancers (Basel). 2023 Aug 8;15(16):4020. doi: 10.3390/cancers15164020.
7
ROS1 genomic rearrangements are rare actionable drivers in microsatellite stable colorectal cancer.ROS1 基因组重排是微卫星稳定结直肠癌中罕见的可操作驱动因素。
Int J Cancer. 2022 Dec 15;151(12):2161-2171. doi: 10.1002/ijc.34257. Epub 2022 Aug 30.